Should Biotechnology Stock Jounce Therapeutics Inc (JNCE) Be in Your Portfolio Wednesday?
Wednesday, April 26, 2023 10:26 AM | InvestorsObserver Analysts
Mentioned in this article
Jounce Therapeutics Inc (JNCE) is near the top in its industry group according to InvestorsObserver. JNCE gets an overall rating of 69. That means it scores higher than 69 percent of stocks. Jounce Therapeutics Inc gets a 85 rank in the Biotechnology industry. Biotechnology is number 30 out of 148 industries.
JNCE has an Overall Score of 69. Find out what this means to you and get the rest of the rankings on JNCE!
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 69 would rank higher than 69 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Jounce Therapeutics Inc Stock Today?
Jounce Therapeutics Inc (JNCE) stock is trading at $1.92 as of 10:26 AM on Wednesday, Apr 26, a drop of -$0.01, or -0.52% from the previous closing price of $1.93. The stock has traded between $1.92 and $1.95 so far today. Volume today is below average. So far 149,917 shares have traded compared to average volume of 3,383,928 shares.
Click Here to get the full Stock Report for Jounce Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
